



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

March 1, 2018

Corporate Relationship Department
M/s. BSE Ltd
Dalal Street, Fort
Mumbai- 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai -400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclosed herewith the Press Release for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

A handwritten signature in black ink that reads "M Adinarayana".

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/ 17 /2017-2018

Press Release

NATCO ANNOUNCES USFDA FILING FOR SOFOSBUVIR TABLETS, 400MG

Hyderabad, India, March 1st, 2018

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced that it has filed an Abbreviated New Drug Application (ANDA) for Sofosbuvir Tablets, 400mg, with the U.S. Federal Drug Administration (USFDA). Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi®.

Natco believes that they are the first to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and expects to be eligible for 180 days of marketing exclusivity upon receiving final FDA approval.

For the 12 months ending Dec. 31, 2017, SOVALDI® had U.S. sales of approximately \$130 million as per Gilead Sciences Inc. unaudited results released for the year ending 31st December, 2017.

Forwarded for favour of publication

For NATCO Pharma Limited

M Adinarayana

M Adinarayana

Company Secretary &

Vice President (Legal & Corp Affairs)